Streetbeat News

Regulatory

VALN

Valneva SE announced that the results of two Phase 2 clinical trials for its Lyme disease vaccine candidate, VLA15, have been published in 'The Lancet Infectious Diseases'. These trials, along with a third Phase 2 trial in pediatric participants, support the design of the current pivotal Phase 3 trial, VALOR.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 3:46 pm

MBOT

Microbot Medical Inc. (NASDAQ:MBOT) shares surged after receiving FDA approval to proceed with human clinical trials for its LIBERTY Endovascular Robotic Surgical System. The company has signed a clinical trial service agreement with a leading academic medical center and is completing biocompatibility tests. The stock saw heavy trading volume, significantly exceeding its 100-day average.

Portfolio Pulse from Erica Kollmann

June 03, 2024 | 3:36 pm

MBOT

Microbot Medical shares are trading higher following the company's announcement of receiving FDA approval to proceed with its pivotal human clinical trial.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 3:34 pm

TD

Fresh allegations have surfaced that a TD banker accepted bribes, expanding the scope of the DOJ probe to Florida. This development could have significant implications for TD's reputation and regulatory standing.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 3:34 pm

NDAQ

EU antitrust regulators are unlikely to seek feedback from rivals and users regarding EEX's proposed remedies for its deal with Nasdaq. The regulators likely view the remedies as insufficient and are expected to open an investigation into the deal. EEX could potentially avoid the investigation by offering more remedies in the coming days, according to sources.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 3:25 pm

GRTX

Galera Therapeutics Inc (NASDAQ:GRTX) shares plummeted by 34.8% to $0.14 after receiving a delisting notice from Nasdaq due to non-compliance with listing standards. Trading will be suspended on June 4, 2024, and the company plans to move to OTC Markets Group.

Portfolio Pulse from Henry Khederian

June 03, 2024 | 3:17 pm

GRTX

Galera Therapeutics shares are trading lower after the company announced it will be delisted by Nasdaq.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 3:16 pm

GPCR

Structure Therapeutics Inc. (NASDAQ:GPCR) announced positive 12-week topline obesity data from its Phase 2a study of GSBR-1290, showing significant weight loss and favorable safety results. The company plans to submit an IND to the FDA in Q3 2024 and initiate a Phase 2b study in Q4 2024.

Portfolio Pulse from Vandana Singh

June 03, 2024 | 3:11 pm

DJIA

NDAQ

QQQ

SPY

The NYSE has resolved a technical issue with price bands from the CTA SIP that caused trading halts. This resolution is expected to stabilize trading activities.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 3:11 pm

ERIC

Ericsson (NASDAQ:ERIC) has announced the conclusion of its US anti-corruption compliance monitorship, which was part of a Deferred Prosecution Agreement (DPA) with the U.S. Department of Justice (DOJ). The monitorship, which began in June 2020, has been successfully completed, and the company's anti-corruption compliance program has met all requirements. Despite this positive development, Ericsson recently reported a 15% year-over-year sales decline and missed revenue expectations, although its EPS beat consensus estimates.

Portfolio Pulse from Lekha Gupta

June 03, 2024 | 3:10 pm